Important security notice Important security notice: CIGP is not associated with thunderplan[.]hk

CIGP is not associated with thunderplan[.]hk, the “Thunder Break” investment scheme or any related WhatsApp group or message and has not authorised or endorsed any of them. Do not send money or personal information in connection with any of them; verify any approach made in CIGP’s name directly with us using the contact details published on this website.

Notis keselamatan penting Notis keselamatan penting: CIGP tidak mempunyai sebarang kaitan dengan thunderplan[.]hk

CIGP tidak mempunyai sebarang kaitan dengan thunderplan[.]hk, skim pelaburan “Thunder Break” atau mana-mana kumpulan atau mesej WhatsApp yang berkaitan dan tidak pernah membenarkan atau menyokong mana-mana satu daripadanya. Jangan hantar wang atau maklumat peribadi berkaitan dengan mana-mana satu daripadanya; sahkan sebarang pendekatan yang dibuat atas nama CIGP secara terus dengan kami menggunakan butiran hubungan yang diterbitkan di laman web ini.

Disclaimer

By accepting this, you are confirming that:

- You acknowledge and agree with our Cookie Policy (Learn more) and our Terms of Use (Learn more)
- You acknowledge and agree that Compagnie d'Investissements et de Gestion Privée (Hong Kong) Limited is licensed and regulated by the Hong Kong Securities and Futures Commission ("SFC") to conduct Type 1 (Dealing in securities), Type 4 (Advising on securities) and Type 9 (Asset management) activities (Learn more), and that it can only provide such regulated activities to Professional Investors according to the Securities and Futures Ordinance (Cap 571. Laws of Hong Kong) and its subsidiary legislation.

Disclaimer

By accepting this, you are confirming that:

- You acknowledge and agree with our Cookie Policy (Learn more) and our Terms of Use (Learn more)
- You acknowledge and agree that Compagnie d'Investissements et de Gestion Privée (Hong Kong) Limited is licensed and regulated by the Hong Kong Securities and Futures Commission ("SFC") to conduct Type 1 (Dealing in securities), Type 4 (Advising on securities) and Type 9 (Asset management) activities (Learn more), and that it can only provide such regulated activities to Professional Investors according to the Securities and Futures Ordinance (Cap 571. Laws of Hong Kong) and its subsidiary legislation.

I decline

Disclaimer

By accepting to visit this website, you are confirming that:

- You acknowledge and agree that all the information presented on this website refer to the activities of CIGP as a group of related companies and not to a specific CIGP entity, subsidiary or branch.

- You acknowledge and understand that in Switzerland, CIGP Compagnie d'Investissements et de Gestion Privée SA provides Portfolio Management services. All of the following services referred to on this website are not provided in Switzerland: Corporate Services (Global Custody, Financing, Transaction Services, Cash Management, Fund Structuring & Administration), Fund Advisory, Direct Investments, and Investment Banking (Global Financing and Sales & Trading).

- To understand the specific services provided in a specific location, please contact the relevant entity via our Contact us form.
- You acknowledge and agree with our Cookie Policy (Learn more) and our Terms of Use (Learn more).

I decline

Sale of a Healthcare Products Distributor in Cambodia

CIGP successfully advised the shareholders of Alliance Pharma (Cambodge) on the sale of a controlling stake to Zuellig Pharma. CIGP leveraged its expertise in financial advisory, experience in the healthcare sector and its local presence in both Europe and Asia.

Transaction Highlights

CIGP acted as the exclusive sell-side financial advisor to the shareholders of Alliance Pharma (Cambodge), a leading healthcare and consumer health products distributor in Cambodia, on the sale of a controlling stake to Zuellig Pharma.

Alliance Pharma (Cambodge) provides sales and marketing, logistics and distribution, product licensing and importation services of pharmaceutical, consumer health and nutrition products for and on behalf of reputable multinational clients. In business since 2001, the company has become the 2nd largest distributor in Cambodia.

Zuellig Pharma is one of the largest healthcare services groups in Asia with the purpose of making healthcare more accessible, by providing world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started almost a hundred years ago and has grown to become a US$13 billion business covering 13 markets with over 10,000 employees. Its people serve over 350,000 medical facilities and work with over 1,000 clients, including the top 20 pharmaceutical companies in the world.

Role of CIGP

Exclusive sell-side advisor in a bilateral discussion: CIGP preformed in-depth financial analysis and valuation of the target company to negotiate an optimal transaction structure on behalf of the shareholders. CIGP worked closely with international law firm Allen & Overy as well as leading local law firm Bun & Associates to finalise the transaction.

Industry experience and local presence: CIGP was able to leverage its experience in the healthcare sector and its presence in Asia to successfully close the transaction. CIGP’s ability to bridge the gap between Asia and the world was key in helping to meet the shareholders’ objectives and preferred strategies.

Secondary Investment in a Smart Logistics Solutions Provider
Sale of a High-End French Bakery’s Asian Franchise